Skip to content
DataLookout
Menu

WILL-EMINCT06998524

A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease

StatusRecruiting
PhasePhase 3
Primary completion (estimated)

At risk: Primary completion moved at least 5 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 22 versions: 19 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Primary completion pushed from Apr 30, 2027 to Oct 6, 2027
    • Study completion pushed from Apr 30, 2029 to Sep 6, 2029
  2. Minor Study sites: 29 to 30
  3. Notable Eligibility criteria expanded, about 17 words
    • Site details revised at 5 of 29 sites
  4. Minor Study sites: 28 to 29v19
  5. Minor Study sites: 27 to 28v17
  6. Study Status, Contacts/Locations, Referencesv16
  7. Minor Primary completion pushed from Mar 30, 2027 to Apr 30, 2027
    • Study completion pushed from Mar 30, 2029 to Apr 30, 2029
    v15
  8. Minor Study sites: 26 to 27v12
  9. Minor Study sites: 24 to 26v11
  10. Minor Study sites: 21 to 24
    • Primary completion date: Dec 31, 2026 to Mar 30, 2027
    • Study completion date: Dec 31, 2028 to Mar 30, 2029
    v10
  11. Minor Study sites: 20 to 21v9
  12. Minor Study sites: 16 to 20v8
  13. Notable Eligibility criteria expanded, about 22 wordsv7 Show 4 more changesShow less
    • Enrollment target: 66 to 75
    • Study sites: 13 to 16
    • Primary completion date: Dec 15, 2027 to Dec 31, 2026
    • Secondary endpoints: 23 to 25
  14. Minor Study sites: 12 to 13v6
  15. Minor Study sites: 9 to 12v5
  16. Minor Study sites: 7 to 9v4
  17. Minor Study sites: 1 to 7
    • Study completion date: May 15, 2029 to Dec 31, 2028
    • Start date changed from estimate of Jun 15, 2025 to Jun 27, 2025
    v3
  18. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v2
  19. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Annualized Bleed Rate (ABR) for Treated Bleeds in the Randomized Arms
Timeframe: From Baseline to at least 24 weeks

Secondary (25)

ABR for All Bleeds in the Randomized Arms
ABR for Treated Spontaneous Bleeds in the Randomized Arms
ABR for Treated Joint Bleeds in the Randomized Arms
Intra-Participant Comparison of the ABR for Treated Bleeds with Prophylactic Emicizumab Versus Prophylactic SOC from the Preceeding Non-Interventional Study (NIS) WP45335
Intra-Participant Comparison of the ABR for All Bleeds with Prophylactic Emicizumab Versus Prophylactic SOC from the Preceeding NIS WP45335
Show 20 moreShow less
Intra-Participant Comparison of the ABR for Treated Spontaneous Bleeds with Prophylactic Emicizumab Versus Prophylactic SOC from the Preceeding NIS WP45335
Intra-Participant Comparison of the ABR for Treated Joint Bleeds with Prophylactic Emicizumab Versus Prophylactic SOC from the Preceeding NIS WP45335
Incidence and Severity of Adverse Events, with Severity Determined According to the World Health Organization (WHO) Toxicity Grading Scale
Incidence and Severity of Thromboembolic Events
Incidence and Severity of Thrombotic Microangiopathy Events
Incidence and Severity of Injection-Site Reactions
Incidence of Adverse Events Leading to Drug Discontinuation
Incidence of Severe Hypersensitivity, Anaphylaxis, or Anaphylactoid Reactions
Incidence of Clinical Laboratory Abnormalities
Trough Plasma Concentration of Emicizumab at Prespecified Timepoints During the Treatment Period
Percentage of Participants with Anti-Drug Antibodies (ADAs) to Emicizumab at Baseline and with ADAs to Emicizumab During the Treatment Period
Change from Baseline in Respiratory Rate Over Time
Change from Baseline in Pulse Rate Over Time
Change from Baseline in Systolic Blood Pressure Over Time
Change from Baseline in Diastolic Blood Pressure Over Time
Change from Baseline in Body Temperature Over Time
Change from Baseline in Electrocardiogram (ECG) Parameters Over Time: QT, QTcF, RR, PR, and QRS Intervals
Change from Baseline in Heart Rate Over Time, as Measured by Electrocardiogram (ECG)
Change from Baseline in the PROMIS-29 Questionnaire Pain Interference Domain Score Over Time
Change from Baseline in the PROMIS-29 Questionnaire Fatigue Domain Score Over Time

Arms and interventions

Arm A (Prior On-Demand SOC): Emicizumab Prophylaxis for 24 WeeksExperimental

Participants who are randomized to Arm A, taking on-demand standard of care (SOC) treatment at the time of study entry (and for at least 24 weeks prior to enrollment), will receive emicizumab SC prophylaxis.

Arm B (Prior On-Demand SOC): On-Demand SOC for 24 WeeksActive comparator

Participants who are randomized to Arm B, taking on-demand standard of care (SOC) treatment at the time of study entry (and for at least 24 weeks prior to enrollment), will continue to receive their current SOC on-demand treatment until Week 24.

Arm C (Prior Prophylaxis SOC): Emicizumab Prophylaxis for 24 WeeksExperimental

Participants who enroll in Arm C, taking SOC prophylactic treatment at the time of study entry and for at least 24 weeks of observation during the preceding NIS WP45335, will receive emicizumab SC prophylaxis.

Treatment Extension Period for All Arms: Emicizumab ProphylaxisExperimental

Participants in Arms A and C who have completed 24 weeks of emicizumab prophylaxis and who derive benefit from emicizumab will have the opportunity to continue to receive emicizumab prophylaxis in the extension period. Participants in Arm B who have completed 24 weeks of SOC on-demand treatment will have the opportunity to receive emicizumab prophylaxis in the extension period.

Drugs: Emicizumab, von Willebrand Factor (VWF) Concentrates, Factor VIII (FVIII) Concentrates, von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates, Bypassing Agents

Sites

30 sites in 14 countries

United States 6, United Kingdom 4, Germany 3, Italy 3, Canada 2, France 2, Japan 2, Spain 2, Belgium 1, Colombia 1, Netherlands 1, Poland 1, South Africa 1, Sweden 1